Norbrook Laboratories Ltd. v. Irish Medicines Board [2001] IEHC 227 (21 December 2001)

Norbrook Laboratories Ltd. v. Irish Medicines Board [2001] IEHC 227 (21 December 2001)

The balance of convenience does not favour maintaining the stay, as public health concerns outweigh Norbrook's claims of reputational and financial loss, especially given the product's suspension in the UK and the lack of evidence that the market gap is being filled by competitors. The stay is therefore discharged and the suspension of the marketing authorisation continues.

Citation
[2001] IEHC 227
Parties
Applicant in Judicial Review Proceedings / Respondent in This Application: Norbrook Laboratories Limited; Respondent in Judicial Review Proceedings / Applicant in This Application: Irish Medicines Board
Jurisdiction
Ireland
Judgment Date
21 December 2001
Procedural Posture
Judicial Review / Interlocutory Application to Discharge Stay Pending Determination of Judicial Review
Outcome
Application to discharge the stay granted; stay discharged; suspension of marketing authorisation continues; costs reserved.
Legal Topics
Judicial Review, Interlocutory Relief, Suspension of Marketing Authorisation, Public Health, Balance of Convenience
Administrative Law Health Law Regulatory Law Judicial Review Interlocutory Relief Suspension of Marketing Authorisation Public Health Balance of Convenience

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 2 Authorities cited 7 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Parties

Norbrook Laboratories Limited

Applicant in Judicial Review Proceedings / Respondent in This Application

Irish Medicines Board

Respondent in Judicial Review Proceedings / Applicant in This Application

Procedural Posture

Judicial Review / Interlocutory Application to Discharge Stay Pending Determination of Judicial Review

Legal Issues

  1. 1 Whether the High Court has jurisdiction to grant a stay of the Irish Medicines Board's decision suspending Norbrook's marketing authorisation for Norocillin LA pending judicial review
  2. 2 Whether the balance of convenience favours maintaining or discharging the stay

Ratio Decidendi

The balance of convenience does not favour maintaining the stay, as public health concerns outweigh Norbrook's claims of reputational and financial loss, especially given the product's suspension in the UK and the lack of evidence that the market gap is being filled by competitors. The stay is therefore discharged and the suspension of the marketing authorisation continues.

Court Disposition

Application to discharge the stay granted; stay discharged; suspension of marketing authorisation continues; costs reserved.

Orders

  • The stay imposed by Mr. Justice O'Neill is discharged.
  • The suspension of Norbrook's marketing authorisation for Norocillin LA continues in force.